Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
6.80
+0.24 (3.66%)
Apr 24, 2025, 10:44 AM EDT - Market open

Quoin Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
5.936.076.584.51.43
Upgrade
Research & Development
3.63.312.671.560.24
Upgrade
Operating Expenses
9.539.389.266.061.67
Upgrade
Operating Income
-9.53-9.38-9.26-6.06-1.67
Upgrade
Interest Expense
---0.71-1.37-0.05
Upgrade
Interest & Investment Income
0.560.690.1--
Upgrade
Other Non Operating Income (Expenses)
0.01-00.08-12.78-
Upgrade
EBT Excluding Unusual Items
-8.96-8.69-9.8-20.21-1.72
Upgrade
Other Unusual Items
--0.42-1.25-0.38
Upgrade
Pretax Income
-8.96-8.69-9.38-21.46-2.1
Upgrade
Net Income
-8.96-8.69-9.38-21.46-2.1
Upgrade
Preferred Dividends & Other Adjustments
--0.07--
Upgrade
Net Income to Common
-8.96-8.69-9.45-21.46-2.1
Upgrade
Shares Outstanding (Basic)
00---
Upgrade
Shares Outstanding (Diluted)
00---
Upgrade
Shares Change (YoY)
420.43%----
Upgrade
EPS (Basic)
-66.90-337.46---
Upgrade
EPS (Diluted)
-66.90-337.46---
Upgrade
EBITDA
-9.43-9.27-9.15-5.96-1.57
Upgrade
D&A For EBITDA
0.10.10.10.10.1
Upgrade
EBIT
-9.53-9.38-9.26-6.06-1.67
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q